Details
In this request, we assessed utilization patterns of Lipidol (ethiodized oil) and other non-oil based iodine imaging agents. Eight patient cohorts were assessed. Two of these cohorts explored utilization of Lipidol and non-oil agents, respectively, without further requirements. Two cohorts further assessed these products with an inclusion requirement of evidence of a hysterosalpingography (HSG) procedure. Two cohorts further assessed these products with an inclusion requirement of evidence of a hysterosalpingography procedure AND required that patients be enrolled in health plans with medical and drug coverage in the 180 days prior to their index date. One cohort independently assessed Omnipaque (iohexol), a non-oil agent, with an inclusion requirement of evidence of an HSG procedure. The final cohort did not specify a product exposure, but rather assessed for all HSG procedures.
The study period includes data from January 1, 2010 to December 31, 2018.
- Report 1: We executed this request on Merative™ MarketScan® Research Databases on June 3, 2020. This report includes all defined cohorts without baseline characteristics.
- Report 2: We executed this request on Merative™ MarketScan® Research Databases on June 3, 2020. This report includes cohorts for lipiodol and non-oil based agents and the applicable baseline characteristics.